When cost stops being the barrier: The new chapter of Ozempic injection in India The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance. #India #Ozempic_injection #upcoming_patent #patent_expiry #dramatically_lower #once-premium_diabetes #weight-loss_drug #drug_accessible #cost_stops #Ozempic
